| 3 Undervalued MedTech Stocks to Consider for Gains in 2025. | | | Despite uncertainty around the Trump administration, tariffs, and economic concerns, the healthcare sector has been striving in 2025. Healthcare companies are often considered a defensive play in uncertain times. Despite economic downturns, consumers are still spending on healthcare. The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, providing excellent long-term investment opportunities as the baby boomer generation ages. The global medical device industry is a big part of healthcare and stands to experience substantial growth in the future. The question now is which companies will emerge as the next big winners? | | | | | Underfollowed and undervalued are just two words to describe the MedTech arena. This may be surprising as the space has high growth potential and includes notable innovative participants. Outside of IPOs, medtech firms raised more than $2.5 billion in the first month of 2025, with six financings of $100 million or more. The pandemic has put the MedTech industry at center stage with unparalleled demand for products. The sector has saved millions of lives and improved the quality of life for millions more around the world | | | | | Additionally, healthcare companies are keen on expanding their valuation and capabilities through M&A with MedTech companies to get a competitive edge. What to expect from MedTech? With a global medical device market size of more than $500 billion, it's not surprising that more investors are showing a keen interest in MedTech companies. And with that market expected to grow to almost $800 billion by 2030, investor interest is expected to certainly intensify! The global medical devices market was valued at $570 billion in 2022 and is projected to reach approximately $996.93 billion by 2032, experiencing a compound annual growth rate (CAGR) of 5.8% from 2023 to 2032. | | | Concurrently, the U.S. market alone is forecasted to reach around $246.51 billion by 2032, growing at a CAGR of 5.6% during this period. The market's expansion is accelerated by the increasing demand for minimally invasive procedures and the need for efficient healthcare delivery systems. Key Insights and Demand: (Per Precedence Research) - The hospitals and clinics segment has accounted for 88.5% of the total revenue share in 2022.
- North American region has dominated the market with 39.9% of the total revenue share in 2022.
The surge in demand for medical devices is influenced by factors such as an aging population, increasing prevalence of chronic diseases, and a focus on improving healthcare infrastructure globally. The demand is also attributed to innovative therapies and ongoing technological advancements in medical devices to address unmet needs in the healthcare sector. What exactly are medical device stocks? Medical device stocks are shares of companies that make and sell medical devices. Medical devices include any appliance, instrument, or machine used to diagnose, treat, or prevent a disease or condition. The World Health Organization estimates that there are roughly 2 million different kinds of medical devices marketed The 2020s are bringing many opportunities for the industry to generate value and growth beyond historic industry norms. As chronic disease cases continue to increase, the healthcare sector stands to rely heavily on advancements in MedTech technology which could be a favorable catalyst for publicly traded companies in the space. It's a competitive and rapidly changing environment and each MedTech company's path to growth has to be uniquely strategic. In this same vein, investors should take note of these 3 promising MedTech stocks that are revolutionizing healthcare while growing shareholder value too.
| | | #1 BioStem Technologies, Inc. (OTCQB: BSEM) | | | Emerging MedTech company BioStem Technologies, Inc. (OTC: BSEM) is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. | | | | | | BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. BSEM has recently announced record preliminary net revenue of $72.5 million for Q1 2025. This is a 73% increase compared to $41.9 million in Q1 2024. The company also ended the quarter with cash on hand at $26.7 million, an increase from $22.8 million on December 31st, 2024. This was the strongest first quarter in the company's history. On the capital markets front, BSEM remains in active review with the SEC regarding its Form 10 registration and uplisting process, and it looks forward to completing this milestone and becoming listed on Nasdaq. The company states its mission is "to discover, develop and produce the most effective regenerative medicine products in the world," and we believe that the company is well on its way to achieving that goal—providing to investors what we believe is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so. BSEM is focused on the diabetic wound care market and the surgical wound care market. 2023 and 2024 were pivotal years for BSEM which has established a solid foundation for the company's future expansion, which now includes a potential uplisting to a senior stock exchange. The company is capturing Wall Street's attention as its share price has risen from around $1 in July of 2023 to as high as $7.00 by year-end. By the end of 2024, shares were nearly $30 a share. Zack's Small Cap Research has a $35.50 price target on shares. What has Zack's SCR had to say? "The company continues to show tremendous growth that is beating even our most optimistic projections. Management released preliminary quarterly and full year 2024 results that bested estimates, with revenues coming in at $102.9 million for the fourth quarter, which resulted in net income of $0.94 per share. The company also posted gross margins of 97% for the quarter and 95% for the year—extremely impressive profitability. The company also noted that cash on the balance sheet at the end of year had grown to $28.2 million. Management also noted that full financial results should be available soon as the company is working through revenue recognition issues with the SEC as part of the uplisting process BSEM is going through with the NASDAQ." The company's portfolio of quality brands includes VENDAJE™, VENDAJE™ AC,VENDAJE™ OPTIC and AMNIOWRAP2. "2024 has been an extraordinary and transformative year for BioStem, defined by record-breaking growth and a series of groundbreaking milestones that underscore our leadership in advanced wound care. Achieving over 1,700% year-over-year revenue growth is a testament to the relentless execution of our strategic initiatives, the innovation behind our products like AmnioWrap2™ and the newly-launched Vendaje AC®, and the dedication of our team." - CEO Jason Matuszewski Ernst & Young LLP (EY US) has announced that Matuszewski is an Entrepreneur Of The Year® 2025 Florida Award Winner! This is a very competitive awards program which speaks in volumes for them to choose BSEM's CEO.
For 40 years, EY US has celebrated ambitious entrepreneurs who are transforming industries, impacting communities and creating long-term value. | | | The company has continued to release positive news throughout the quarter including initiating a new study and exciting study results. BSEM has initiated the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus standard of care for patients suffering with non-healing diabetic foot ulcers. BSEM has also released study results that showed the company's signature technology, BioREtain, showed superior performance over the traditional standard of care. According to the company, in this study, researchers conducted a retrospective analysis to evaluate the effectiveness of a sterile, dehydrated amnion/chorion membrane processed using a proprietary method (BioREtain-AC) compared to a cohort of patients treated with standard of care measures in healing hard-to-heal diabetic foot ulcers in a real-world environment. A total of 21 subjects met the study's inclusion criteria, which included factors such as wound type, medical history, and previous treatment involving the BioREtain-AC placental membrane product. The wounds in the study were considerably larger than those typically included in randomized controlled trials, averaging nearly 14 cm², compared to an average wound size of about 5 cm² in most trials. The study demonstrated that patients treated with BioREtain experienced an 8.53% higher probability of achieving full wound closure compared to the standard of care group after 12 weeks. For those wounds that did not achieve complete closure, the BioREtain group still showed a 93.6% improvement in expected area reduction, while the standard of care group stalled or grew larger. Late last month the company announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two design patents and one utility patent covering the Company's novel fenestrated human placental allograft designs and compositions manufactured using the BioREtain® process. Jason Matuszewski, Chief Executive Officer of BioStem Technologies, commented: "BioStem is actively expanding its patent portfolio to accelerate product innovation and drive the development of new products that elevate the standard of wound care. These newly granted patents play a pivotal role in the advancement of our next-generation placental allograft technologies." And on another exciting front, BSEM recently announced that it has filed with the SEC to register its shares pursuant to the Securities Exchange Act of 1934, which is an important step in its plan to uplist to the Nasdaq stock exchange. With BSEM's revenues skyrocketing, game-changing partnerships, a successful capital raise, and the start of a crucial clinical trial for diabetic foot ulcers… this all reads like a recipe for tremendous shareholder value. | | | #2 Intuitive Surgical (NASDAQ: ISRG) Priced at nearly $500 a share and with a market cap of almost $200B, Intuitive Surgical stands out among many Medtech stocks by its size alone. | | | | | | Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company sells the da Vinci surgical robotic system for minimally invasive surgical procedures. ISRG is a key player in both the S&P 500 and NASDAQ-100 indices and earns recognition as a stable and widespread provider of high-end, specialized medical equipment. The company revolutionizes surgery to enhance provider performance and patient outcomes, standing out from competitors focusing on conventional medical hardware. ISRG recently reported first quarter EPS of $1.81, $0.07 better than the analyst estimate of $1.74. Revenue for the quarter came in at $2.25B versus the consensus estimate of $2.19B. Q1 Highlights - Worldwide da Vinci procedures grew approximately 17% compared with the first quarter of 2024.
- The Company placed 367 da Vinci surgical systems, compared with 313 in the first quarter of 2024. The first quarter 2025 da Vinci surgical system placements included 147 da Vinci 5 systems, compared with 8 in the first quarter of 2024.
- The Company grew its da Vinci surgical system installed base to 10,189 systems as of March 31, 2025, an increase of 15% compared with 8,887 as of March 31, 2024.
- First quarter 2025 revenue of $2.25 billion increased 19% compared with $1.89 billion in the first quarter of 2024.
- First quarter 2025 GAAP net income attributable to Intuitive was $698 million, or $1.92 per diluted share, compared with $545 million, or $1.51 per diluted share, in the first quarter of 2024.
- First quarter 2025 non-GAAP* net income attributable to Intuitive was $662 million, or $1.81 per diluted share, compared with $541 million, or $1.50 per diluted share, in the first quarter of 2024.
The company has forecasted its financial performance for fiscal year 2025, estimating a gross profit margin between 65% and 66.5%. Alongside this, they anticipate operating expenses to rise by 10% to 14% over the same period. | | | Based on the one-year price targets offered by 26 analysts, the average target price for Intuitive Surgical Inc. is $624.07 with a high estimate of $700.00 and a low estimate of $510.00. #3 Zimmer Biomet Holdings, Inc. (NYZE: ZBH) | | | With a market cap of almost $20B, Zimmer Biomet Holdings is another formidable player in the MedTech space with a remarkable size. | | | | | | Headquartered in Warsaw, IN, Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, the company markets products in more than 100 countries. | | | In the last reported quarter, the company's earnings of $2.31 surpassed the Zacks Consensus Estimate by 0.4%. ZBH beat on earnings in three of the trailing four quarters and missed on one occasion, the average earnings surprise being 1.28%. Paragon 28, Inc., a company specializing in surgical and medical instruments with a market capitalization of $1.1 billion, has recently completed a significant merger with Gazelle Merger Sub I, Inc., a subsidiary of Zimmer Biomet Holdings., according to an 8-K filing with the U.S. Securities and Exchange Commission. The transaction transforms Paragon 28 into a wholly owned subsidiary of Zimmer Biomet. | | | | | | ZBH has also become the first and only medical device partner for the sport of pickleball. As partners of Zimmer Biomet, the Association of Pickleball Players (APP), Professional Pickleball Association (PPA Tour), and USA Pickleball, the National Governing Body for pickleball, have aligned with the company to alleviate pain and improve the quality of life for the 48.3 million pickleball players1 and millions of spectators across the United States. Of those 48.3 million players, more than half of core players—those who play eight or more times a year—are 55 or older, and almost a third are 65-plus. Zimmer Biomet is an official partner to the APP, PPA Tour, and USA Pickleball and will present interactive, onsite activations showcasing product innovations, and educating and raising awareness of the importance of joint health. Several Wall Street analysts regularly cover Zimmer Biomet Holdings (ZBH), including those at firms like BTIG, Canaccord Genuity, Citigroup, and Cleveland Research, according to Zimmer Biomet's investor relations page. Other analysts who have provided ratings and price targets for ZBH include those at Barclays, JMP Securities, Needham & Company, Raymond James, and Royal Bank of Canada, according to MarketBeat. The average target price for Zimmer Biomet Holdings (ZBH) stock is around $122.06, according to a consensus of analysts. | | | In summary… Advances in MedTech give promising hope for patient treatment, improving outcomes, lowering hospital admissions and fatalities, achieving cost savings, and alleviating the workload on healthcare staff, thus creating a market for medical devices that is forecast to grow and expand over the next five years, according to a new healthcare market research report from Kalorama Information. "The Medtech industry is in a perpetual state of evolution, consistently advancing through the continuous development of new technologies, equipment, tests, and devices," said Daniel Granderson, editor for Kalorama Information. "These innovations in the medical device market have transformative effects, significantly contributing to life-changing outcomes that empower patients to lead longer, healthier, and more productive lives." | | | | | | The innovative MedTech companies above may catapult to the forefront of the space and could be poised for monumental growth and breakthroughs in 2025! Add them to your radar! | | | Disclaimer: We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Trading wire nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Trading wire. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Trading wire makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Some of the content on this website contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results. From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Trading Wire encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content. Trading wire, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Trading wire control, endorse, or guarantee any content found in such sites. Trading wire does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Trading wire , its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Trading wire,, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Trading wire uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm. Generally, the information regarding a company profiled or discussed on this website is provided from public sources tradingwire.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Trading wire has no obligation to update any of the information provided. Trading wire , its owners, officers, directors, contractors and employees are not responsible for errors and omissions. Income Disclaimer Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions. Trading wire has been retained by Biostem Technologies (OTC:BSEM) to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from Biostem Technologies (OTC:BSEM). Questions regarding this website may be sent to editor@tradingwire.com Trading Wire has an ongoing agreement with Biostem Technologies (OTC:BSEM) for the total sum of $2,214,000.00 This agreement is for the marketing of Biostem Technologies (OTC:BSEM) which services include the issuance of this release and other opinions that we release concerning of Biostem Technologies (OTC:BSEM). The Owner(s) of Trading Wire own 4,365 free trading shares of Biostem Technologies (OTCS:BSEM) and 63,333 restricted shares. for the purpose of this disclaimer assume that the owners of Trading Wire will sell every share at any time. Trading Wire has not investigated the background of Biostem Technologies (OTC:BSEM) the hiring party, or Biostem Technologies (OTC:BSEM) Anyone viewing this newsletter should assume Biostem Technologies (OTC:BSEM) or affiliates of Biostem Technologies (OTC:BSEM) own shares of the Biostem Technologies (OTC:BSEM)) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Trading Wire has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Biostem Technologies (OTC:BSEM) | | | | |
